{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:04:16Z","timestamp":1791227056708,"version":"4.1.0"},"reference-count":137,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Despite its effectiveness in controlling plasma viremia, antiretroviral therapy (ART) cannot target proviral DNA, which remains an obstacle to HIV-1 eradication. When treatment is interrupted, the reservoirs can act as a source of viral rebound, highlighting the value of proviral DNA as an additional source of information on an individual\u2019s overall resistance burden. In cases where the viral load is too low for successful HIV-1 RNA genotyping, HIV-1 DNA can help identify resistance mutations in treated individuals. The absence of treatment history, the need to adjust ART despite undetectable viremia, or the presence of LLV further support the use of genotypic resistance tests (GRTs) on HIV-1 DNA. Conventionally, GRTs have been achieved through Sanger sequencing, but the advances in NGS are leading to an increase in its use, allowing the detection of minority variants present in less than 20% of the viral population. The clinical significance of these mutations remains under debate, with interpretations varying based on context. Additionally, proviral DNA is subject to APOBEC3-induced hypermutation, which can lead to defective, nonviable viral genomes, a factor that must be considered when performing GRTs on HIV-1 DNA.<\/jats:p>","DOI":"10.3390\/v16111697","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T09:10:44Z","timestamp":1730279444000},"page":"1697","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Archived HIV-1 Drug Resistance Mutations: Role of Proviral HIV-1 DNA Genotype for the Management of Virological Responder People Living with HIV"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7381-9071","authenticated-orcid":false,"given":"Roberta","family":"Campagna","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4911-7301","authenticated-orcid":false,"given":"Chiara","family":"Nonne","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-2939","authenticated-orcid":false,"given":"Guido","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6400-9168","authenticated-orcid":false,"given":"Ombretta","family":"Turriziani","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","article-title":"Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection","volume":"24","author":"Colby","year":"2018","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1073\/pnas.95.15.8869","article-title":"Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection","volume":"95","author":"Chun","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1172\/JCI136227","article-title":"The multifaceted nature of HIV latency","volume":"130","author":"Dufour","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101301","DOI":"10.1016\/j.coviro.2023.101301","article-title":"HIV persistence: Silence or resistance?","volume":"59","author":"Pasternak","year":"2023","journal-title":"Curr. Opin. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/QAD.0000000000002465","article-title":"High levels of genetically-intact HIV in HLA-DR+ memory T-cells indicates their value for reservoir studies","volume":"34","author":"Horsburgh","year":"2020","journal-title":"AIDS"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Coffin, J.M., and Hughes, S.H. (2021). Clonal Expansion of Infected CD4+ T Cells in People Living with HIV. Viruses, 13.","DOI":"10.3390\/v13102078"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00126334-200404150-00005","article-title":"Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy","volume":"35","author":"Verhofstede","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dki038","article-title":"The latent HIV-1 reservoir in patients undergoing HAART: An archive of pre-HAART drug resistance","volume":"55","author":"Plum","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1097\/00002030-200010200-00007","article-title":"Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART","volume":"14","author":"Wang","year":"2000","journal-title":"AIDS"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s40121-022-00676-y","article-title":"HIV DNA Sequencing to Detect Archived Antiretroviral Drug Resistance","volume":"11","author":"Geretti","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chu, C., Armenia, D., Walworth, C., Santoro, M.M., and Shafer, R.W. (2022). Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells. Clin. Microbiol. Rev., 35.","DOI":"10.1128\/cmr.00052-22"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/j.1469-0691.2010.03329.x","article-title":"Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection","volume":"16","author":"Turriziani","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1128\/JCM.41.4.1760-1762.2003","article-title":"Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing","volume":"41","author":"Sarmati","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jcv.2004.11.006","article-title":"Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART","volume":"33","author":"Chew","year":"2005","journal-title":"J. Clin. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/QAI.0b013e3180315515","article-title":"Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals","volume":"44","author":"Turriziani","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1086\/518287","article-title":"Use of Peripheral Blood DNA for Genotype Antiretroviral Resistance Testing in Drug-Naive HIV-Infected Subjects","volume":"44","author":"Vicenti","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","first-page":"56","article-title":"Comparison of HIV-1 resistance profiles in plasma RNA versus PBMC DNA in heavily treated patients in Honduras, a resource-limited country","volume":"3","author":"Diallo","year":"2012","journal-title":"Int. J. Mol. Epidemiol. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/jmv.21261","article-title":"Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART","volume":"80","author":"Saracino","year":"2008","journal-title":"J. Med. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00126334-200309010-00001","article-title":"Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year","volume":"34","author":"Bi","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/jac\/dky130","article-title":"Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART","volume":"73","author":"Nouchi","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1468-1293.2012.01002.x","article-title":"Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication","volume":"13","author":"Delaugerre","year":"2012","journal-title":"HIV Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jac\/dkq544","article-title":"Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia","volume":"66","author":"Wirden","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/jac\/dkw146","article-title":"Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate combination","volume":"71","author":"Allavena","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcv.2018.04.001","article-title":"Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment","volume":"104","author":"Armenia","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cid\/ciac762","article-title":"Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort","volume":"76","author":"Elvstam","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1097\/QAD.0000000000002588","article-title":"The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa","volume":"34","author":"Inzaule","year":"2020","journal-title":"AIDS"},{"key":"ref_29","unstructured":"(2024, August 27). HIV\/AIDS Treatment Guidelines|Clinicalinfo.HIV.gov, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/hiv.13541","article-title":"Low-level HIV viraemia during antiretroviral therapy: Longitudinal patterns and predictors of viral suppression","volume":"25","author":"Zazzi","year":"2024","journal-title":"HIV Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","article-title":"Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: A multicentre cohort study","volume":"18","author":"Hermans","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Antiretroviral Therapy Cohort Collaboration (ART-CC), Vandenhende, M.-A., Ingle, S., May, M., Chene, G., Zangerle, R., Van Sighem, A., Gill, M.J., Schwarze-Zander, C., and Hernandez-Novoa, B. (2015). Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS, 29, 373\u2013383.","DOI":"10.1097\/QAD.0000000000000544"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jcv.2016.07.007","article-title":"Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA","volume":"82","author":"Zaccarelli","year":"2016","journal-title":"J. Clin. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"104657","DOI":"10.1016\/j.jcv.2020.104657","article-title":"Drug resistance mutations in proviral DNA of HIV-infected patients with low level of viremia","volume":"132","author":"Villalobos","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.2147\/IDR.S406188","article-title":"Role of Proviral HIV-1 DNA Genotyping for People Living with HIV (PLWH) Who Had Low-Level Viremia While Receiving Antiretroviral Therapy","volume":"16","author":"Lv","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Liu, J., Li, C., Sun, Y., Fu, C., Wei, S., Zhang, X., Ma, J., Zhao, Q., and Huo, Y. (2024). Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City, China. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-60965-z"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"106492","DOI":"10.1016\/j.ijantimicag.2021.106492","article-title":"Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV","volume":"59","author":"Armenia","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1093\/jac\/dkae236","article-title":"Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: Data from the PRESTIGIO Registry","volume":"79","author":"Armenia","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"ofz533","DOI":"10.1093\/ofid\/ofz533","article-title":"Clinical Outcomes Following the Use of Archived Proviral HIV-1 DNA Genotype to Guide Antiretroviral Therapy Adjustment","volume":"7","author":"Ellis","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Wang, R., Wright, J., Saggu, P., Ait-Khaled, M., Moodley, R., Parry, C.M., Lutz, T., Podzamczer, D., Moore, R., and G\u00f3rgolas Hern\u00e1ndez-Mora, M. (2023). Assessing the Virologic Impact of Archived Resistance in the Dolutegravir\/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144. Viruses, 15.","DOI":"10.3390\/v15061350"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1097\/QAD.0000000000001581","article-title":"Dolutegravir-based regimen maintains virological success in a patient with archived mutations to integrase inhibitors","volume":"31","author":"Mazzuti","year":"2017","journal-title":"AIDS"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: A multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: A randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1097\/QAD.0000000000003311","article-title":"Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment experience patients","volume":"36","author":"Busca","year":"2022","journal-title":"AIDS"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jac\/dkae164","article-title":"The RT M184V resistance mutation clearance in the reservoir is mainly related to CD4 nadir and viral load zenith independently of therapeutic regimen type","volume":"79","author":"Teyssou","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature00939","article-title":"Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein","volume":"418","author":"Sheehy","year":"2002","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.sbi.2015.04.004","article-title":"HIV suppression by host restriction factors and viral immune evasion","volume":"31","author":"Jia","year":"2015","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.tibs.2016.05.001","article-title":"The APOBEC Protein Family: United by Structure, Divergent in Function","volume":"41","author":"Salter","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Xu, W.K., Byun, H., and Dudley, J.P. (2020). The Role of APOBECs in Viral Replication. Microorganisms, 8.","DOI":"10.20944\/preprints202011.0013.v1"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1126\/science.3006244","article-title":"Replicative and cytopathic potential of HTLV-III\/LAV with sor gene deletions","volume":"231","author":"Sodroski","year":"1986","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.coi.2004.05.006","article-title":"Recent insights into HIV-1 Vif","volume":"16","author":"Navarro","year":"2004","journal-title":"Curr. Opin. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"10504","DOI":"10.1074\/jbc.M114.626903","article-title":"Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein","volume":"290","author":"Pery","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.antiviral.2016.11.001","article-title":"An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation","volume":"136","author":"Bennett","year":"2016","journal-title":"Antiviral Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/nm945","article-title":"The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif","volume":"9","author":"Sheehy","year":"2003","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"York, A., Kutluay, S.B., Errando, M., and Bieniasz, P.D. (2016). The RNA Binding Specificity of Human APOBEC3 Proteins Resembles That of HIV-1 Nucleocapsid. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005833"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.bbrc.2011.08.009","article-title":"Direct evidence that RNA inhibits APOBEC3G ssDNA cytidine deaminase activity","volume":"412","author":"McDougall","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nsmb758","article-title":"Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome","volume":"11","author":"Yu","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature01709","article-title":"Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts","volume":"424","author":"Mangeat","year":"2003","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Villanova, F., Barreiros, M., and Leal, \u00c9. (2020). Is the tryptophan codon of gene vif the Achilles\u2019 heel of HIV-1?. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0225563"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/bioinformatics\/16.4.400","article-title":"Detecting hypermutations in viral sequences with an emphasis on G \u2192 A hypermutation","volume":"16","author":"Rose","year":"2000","journal-title":"Bioinforma. Oxf. Engl."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1128\/JVI.79.17.11513-11516.2005","article-title":"APOBEC3G\/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia","volume":"79","author":"Jin","year":"2005","journal-title":"J. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1093\/nar\/gkq174","article-title":"Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: Implications for HIV-1 restriction","volume":"38","author":"Refsland","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"De Pasquale, M., Kourteva, Y., Allos, T., and D\u2019Aquila, R.T. (2013). Lower HIV provirus levels are associated with more APOBEC3G protein in blood resting memory CD4+ T lymphocytes of controllers in vivo. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076002"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1128\/JVI.03464-14","article-title":"Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers","volume":"89","author":"Kikuchi","year":"2015","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cub.2004.12.068","article-title":"Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity","volume":"15","author":"Newman","year":"2005","journal-title":"Curr. Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"8450","DOI":"10.1128\/JVI.00839-06","article-title":"Antiviral potency of APOBEC proteins does not correlate with cytidine deamination","volume":"80","author":"Bishop","year":"2006","journal-title":"J. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1128\/JVI.02680-05","article-title":"Biochemical activities of highly purified, catalytically active human APOBEC3G: Correlation with antiviral effect","volume":"80","author":"Iwatani","year":"2006","journal-title":"J. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1128\/JVI.00272-07","article-title":"Human Immunodeficiency Virus Type 1 cDNAs Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration","volume":"81","author":"Mbisa","year":"2007","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1093\/nar\/gkm750","article-title":"Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G","volume":"35","author":"Iwatani","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Bishop, K.N., Verma, M., Kim, E.-Y., Wolinsky, S.M., and Malim, M.H. (2008). APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog., 4.","DOI":"10.1371\/journal.ppat.1000231"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Adolph, M.B., Webb, J., and Chelico, L. (2013). Retroviral Restriction Factor APOBEC3G Delays the Initiation of DNA Synthesis by HIV-1 Reverse Transcriptase. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0064196"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/1873-3468.12954","article-title":"AID recruits the RNA exosome to degrade HIV-1 nascent transcripts through interaction with the Tat-P-TEFb-TAR RNP complex","volume":"592","author":"Wang","year":"2018","journal-title":"FEBS Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1093\/nar\/gkt527","article-title":"Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses","volume":"41","author":"Savoie","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.1089591","article-title":"Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex","volume":"302","author":"Yu","year":"2003","journal-title":"Science"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1098\/rstb.2008.0185","article-title":"APOBEC proteins and intrinsic resistance to HIV-1 infection","volume":"364","author":"Malim","year":"2009","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_77","first-page":"371","article-title":"Vif hijacks CBF-\u03b2 to degrade APOBEC3G and promote HIV-1 infection","volume":"481","author":"Kim","year":"2011","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Guerrero, S., Libre, C., Batisse, J., Mercenne, G., Richer, D., Laumond, G., Decoville, T., Moog, C., Marquet, R., and Paillart, J.-C. (2016). Translational regulation of APOBEC3G mRNA by Vif requires its 5\u2032UTR and contributes to restoring HIV-1 infectivity. Sci. Rep., 6.","DOI":"10.1038\/srep39507"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1097-2765(03)00353-8","article-title":"HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability","volume":"12","author":"Stopak","year":"2003","journal-title":"Mol. Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"11398","DOI":"10.1128\/JVI.77.21.11398-11407.2003","article-title":"The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity","volume":"77","author":"Kao","year":"2003","journal-title":"J. Virol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/nar\/gkp1009","article-title":"HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation","volume":"38","author":"Mercenne","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1017\/S1462399409001343","article-title":"Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: Implications for therapeutics","volume":"12","author":"Albin","year":"2010","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/QAD.0b013e32833e515a","article-title":"Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals","volume":"24","author":"Fourati","year":"2010","journal-title":"AIDS"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41564-017-0063-9","article-title":"Deep sequencing of HIV-1 reverse transcripts reveals the multifaceted antiviral functions of APOBEC3G","volume":"3","author":"Pollpeter","year":"2018","journal-title":"Nat. Microbiol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Wood, N., Bhattacharya, T., Keele, B.F., Giorgi, E., Liu, M., Gaschen, B., Daniels, M., Ferrari, G., Haynes, B.F., and McMichael, A. (2009). HIV evolution in early infection: Selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000414"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/JVI.00056-10","article-title":"APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis","volume":"84","author":"Sadler","year":"2010","journal-title":"J. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/QAI.0000000000000689","article-title":"Impact of APOBEC Mutations on CD8+ T Cell Recognition of HIV Epitopes Varies Depending on the Restricting HLA","volume":"70","author":"Squires","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Monajemi, M., Woodworth, C.F., Zipperlen, K., Gallant, M., Grant, M.D., and Larijani, M. (2014). Positioning of APOBEC3G\/F Mutational Hotspots in the Human Immunodeficiency Virus Genome Favors Reduced Recognition by CD8+ T Cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0093428"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"10402","DOI":"10.1128\/JVI.01223-10","article-title":"Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure","volume":"84","author":"Kim","year":"2010","journal-title":"J. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0092-8674(01)00234-3","article-title":"HIV-1 sequence variation: Drift, shift, and attenuation","volume":"104","author":"Malim","year":"2001","journal-title":"Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/jac\/dku426","article-title":"Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: A multicohort European case\u2013control study using centralized ultrasensitive 454 pyrosequencing","volume":"70","author":"Schuurman","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Kim, E.-Y., Lorenzo-Redondo, R., Little, S.J., Chung, Y.-S., Phalora, P.K., Maljkovic Berry, I., Archer, J., Penugonda, S., Fischer, W., and Richman, D.D. (2014). Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004281"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Cuevas, J.M., Geller, R., Garijo, R., L\u00f3pez-Aldeguer, J., and Sanju\u00e1n, R. (2015). Extremely High Mutation Rate of HIV-1 In Vivo. PLoS Biol., 13.","DOI":"10.1371\/journal.pbio.1002251"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.4156","article-title":"Defective proviruses rapidly accumulate during acute HIV-1 infection","volume":"22","author":"Bruner","year":"2016","journal-title":"Nat. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","article-title":"A quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"Bruner","year":"2019","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.immuni.2018.04.030","article-title":"Targeting the Latent Reservoir for HIV-1","volume":"48","author":"Sengupta","year":"2018","journal-title":"Immunity"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"18692","DOI":"10.1073\/pnas.2006816117","article-title":"Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA","volume":"117","author":"Simonetti","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent non-induced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Ho","year":"2013","journal-title":"Cell"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1172\/JCI124291","article-title":"Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy","volume":"129","author":"Einkauf","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1093\/jac\/dkad344","article-title":"Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir + lamivudine simplification in the ANRS 167 LAMIDOL trial","volume":"78","author":"Mazouz","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"105551","DOI":"10.1016\/j.jcv.2023.105551","article-title":"Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals","volume":"168","author":"Armenia","year":"2023","journal-title":"J. Clin. Virol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e00105-18","DOI":"10.1128\/JCM.00105-18","article-title":"Comparison of an In Vitro Diagnostic Next-Generation Sequencing Assay with Sanger Sequencing for HIV-1 Genotypic Resistance Testing","volume":"56","author":"Tzou","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jviromet.2016.11.008","article-title":"MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing","volume":"240","author":"Huber","year":"2017","journal-title":"J. Virol. Methods"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/jmv.24872","article-title":"Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples","volume":"89","author":"Trabaud","year":"2017","journal-title":"J. Med. Virol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Tzou, P.L., Kosakovsky Pond, S.L., Avila-Rios, S., Holmes, S.P., Kantor, R., and Shafer, R.W. (2020). Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0225352"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cell.2021.12.011","article-title":"Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses","volume":"185","author":"Einkauf","year":"2022","journal-title":"Cell"},{"key":"ref_107","unstructured":"(2024, August 27). HIV Drug Resistance Database. Available online: https:\/\/hivdb.stanford.edu\/."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/biot.201200153","article-title":"Stepping stones in DNA sequencing","volume":"7","author":"Stranneheim","year":"2012","journal-title":"Biotechnol. J."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Manyana, S., Gounder, L., Pillay, M., Manasa, J., Naidoo, K., and Chimukangara, B. (2021). HIV-1 Drug Resistance Genotyping in Resource Limited Settings: Current and Future Perspectives in Sequencing Technologies. Viruses, 13.","DOI":"10.3390\/v13061125"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.virusres.2016.10.019","article-title":"Deep sequencing for HIV-1 clinical management","volume":"239","author":"Paredes","year":"2017","journal-title":"Virus Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/COH.0000000000000344","article-title":"Future technologies for monitoring HIV drug resistance and cure","volume":"12","author":"Parikh","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/365671a0","article-title":"Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing","volume":"365","author":"Larder","year":"1993","journal-title":"Nature"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1128\/JCM.43.1.406-413.2005","article-title":"Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis","volume":"43","author":"Palmer","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/QAD.0000000000000267","article-title":"Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure","volume":"28","author":"Mohamed","year":"2014","journal-title":"AIDS"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Slatko, B.E., Gardner, A.F., and Ausubel, F.M. (2018). Overview of Next Generation Sequencing Technologies. Curr. Protoc. Mol. Biol., 122.","DOI":"10.1002\/cpmb.59"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4","DOI":"10.20892\/j.issn.2095-3941.2018.0055","article-title":"Next-generation sequencing and its clinical application","volume":"16","author":"Qin","year":"2019","journal-title":"Cancer Biol. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1093\/jac\/dku278","article-title":"Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: Implications for use in low- and middle-income countries","volume":"69","author":"Ekici","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1093\/jac\/dky315","article-title":"Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia","volume":"73","author":"Rodriguez","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"104207","DOI":"10.1016\/j.jcv.2019.104207","article-title":"Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay","volume":"121","author":"Alidjinou","year":"2019","journal-title":"J. Clin. Virol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Lee, E.R., Parkin, N., Jennings, C., Brumme, C.J., Enns, E., Casadell\u00e0, M., Howison, M., Coetzer, M., Avila-Rios, S., and Capina, R. (2020). Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-58544-z"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/QAI.0000000000003195","article-title":"Brief Report: Comparative Analysis of Pre-existing HIV Drug Resistance Mutations in Proviral DNA Using Next-Generation Sequencing and Routine HIV RNA Genotyping","volume":"93","author":"Gaitan","year":"2023","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Arias, A., L\u00f3pez, P., S\u00e1nchez, R., Yamamura, Y., and Rivera-Amill, V. (2018). Sanger and Next Generation Sequencing Approaches to Evaluate HIV-1 Virus in Blood Compartments. Int. J. Environ. Res. Public Health, 15.","DOI":"10.3390\/ijerph15081697"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/cid\/ciy881","article-title":"Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial","volume":"69","author":"Derache","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/QAD.0000000000002134","article-title":"Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women","volume":"33","author":"Milne","year":"2019","journal-title":"AIDS"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3018(18)30177-2","article-title":"Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: A multi-country nested case-control study","volume":"5","author":"Inzaule","year":"2018","journal-title":"Lancet HIV"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e29273","DOI":"10.1002\/jmv.29273","article-title":"Validation of an HIV whole genome sequencing method for HIV drug resistance testing in an Australian clinical microbiology laboratory","volume":"95","author":"Jenkins","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"\u00c1vila-R\u00edos, S., Parkin, N., Swanstrom, R., Paredes, R., Shafer, R., Ji, H., and Kantor, R. (2020). Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations. Viruses, 12.","DOI":"10.3390\/v12060617"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/jac\/dkab149","article-title":"Assessment of intra-sample variability in HIV-1 DNA drug resistance genotyping","volume":"76","author":"Bocket","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/QAD.0000000000001948","article-title":"HIV DNA Levels and Decay in a Cohort of 111 Long-Term Virally Suppressed Patients","volume":"32","author":"Golob","year":"2018","journal-title":"AIDS"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12977-018-0448-8","article-title":"The role of integration and clonal expansion in HIV infection: Live long and prosper","volume":"15","author":"Anderson","year":"2018","journal-title":"Retrovirology"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Vicenti, I., Dragoni, F., Giannini, A., Casabianca, A., Lombardi, F., Di Sante, L., Turriziani, O., Racca, S., Paolucci, S., and Lai, A. (2022). External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-07196-2"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/infdis\/jix338","article-title":"Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1\u2013Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing","volume":"216","author":"Clutter","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/cix1070","article-title":"Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen","volume":"66","author":"Raymond","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_134","first-page":"1178633717749597","article-title":"Human Immunodeficiency Virus Resistance Testing Technologies and Their Applicability in Resource-Limited Settings of Africa","volume":"10","author":"Nasir","year":"2017","journal-title":"Infect. Dis."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/03008870310009632","article-title":"Phenotypic resistance testing","volume":"106","author":"Andreoni","year":"2003","journal-title":"Scand. J. Infect. Dis. Suppl."},{"key":"ref_136","unstructured":"(2024, October 27). HIV Drug Resistance Testing. Available online: https:\/\/stanfordhealthcare.org\/medical-conditions\/sexual-and-reproductive-health\/hiv-aids\/treatments\/hiv-drug-resistance-testing.html."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","article-title":"HIV-1 drug resistance and resistance testing","volume":"46","author":"Clutter","year":"2016","journal-title":"Infect. Genet. Evol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/11\/1697\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:23:51Z","timestamp":1760113431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/11\/1697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":137,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["v16111697"],"URL":"https:\/\/doi.org\/10.3390\/v16111697","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]}}}